Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Common ADHD drug confers benefits for lower urinary tract in children

29 Jun 2020

Use of the prescription stimulant methylphenidate appears to also exert a positive effect on the lower urinary tract in children with attention deficit hyperactivity disorder (ADHD) but without voiding dysfunction, specifically increasing voided volume and bladder capacity, as shown in a study.

The study included 43 children (mean age, 11.84 years; 70.9 percent boys) with ADHD but without voiding dysfunction and 39 healthy participants (mean age, 11.24 years; 71.8 percent boys). All patients in the ADHD group were given the stimulant following baseline screening.

Researchers evaluated lower urinary tract symptoms (LUTS) and quality of life, in addition to uroflowmetry test results and postvoiding residual volume (PVRV), in both groups at baseline and 4 weeks later. They used the dysfunctional voiding scoring system questionnaire to score LUTS, and ultrasound to measure postvoiding residual volume.

Results showed that at week 4, methylphenidate treatment resulted in significant increases from baseline in voided volume (p=0.001) and bladder capacity (p=0.002). These improvements were not observed in the control group.

While unclear, the mechanism underlying the favourable effect of the stimulant on voided volume and bladder capacity may be attributed to the dopaminergic and noradrenergic effects of the drug, according to the researchers. However, they acknowledged that medication with methylphenidate may not necessarily produce clinically significant improvements in LUTS in ADHD patients diagnosed with voiding dysfunction.

More studies are needed to evaluate the effects of the drug on LUTS in a urodynamic study in ADHD patients with voiding dysfunction to enhance the reliability of the present data.

Editor's Recommendations
Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.